ConductScience.org, home

Paper39092437

Affinity enhancement of polo-like kinase 1 polo box domain-binding ligands by a bivalent approach using a covalent kinase-binding component.

Tsuji K and 2 others. RSC Chem Biol, 2024. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Affinity enhancement of polo-like kinase 1 polo box domain-binding ligands by a bivalent approach using a covalent kinase-binding component. Papers, record 39092437. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39092437

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Affinity enhancement of polo-like kinase 1 polo box domain-binding ligands by a bivalent approach using a covalent kinase-binding component.
PubMed
Journal
RSC Chem Biol
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.92, provisional
iCite
Revised in PubMed
2024-08-03
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tsuji KKoheihttps://orcid.org/0000-0003-4773-8793
2Tamamura HHirokazuhttps://orcid.org/0000-0003-2788-2579
3Burke TR JrTerrence Rhttps://orcid.org/0000-0001-9925-8586

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
130395539PLK1: a promising and previously unexplored target in double-hit lymphoma.J Clin Invest2018https://conductscience.org/library/papers/30395539PubMed
226662918Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.Chembiochem2016https://conductscience.org/library/papers/26662918PubMed
323159568Non-proteinogenic amino acids in the pThr-2 position of a pentamer peptide that confer high binding affinity for the polo box domain (PBD) of polo-like kinase 1 (Plk1).Bioorg Med Chem Lett2012https://conductscience.org/library/papers/23159568PubMed
422570300Peptoid-Peptide hybrid ligands targeting the polo box domain of polo-like kinase 1.Chembiochem2012https://conductscience.org/library/papers/22570300PubMed
528721210Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents.F1000Res2017https://conductscience.org/library/papers/28721210PubMed
631014020Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors.Molecules2019https://conductscience.org/library/papers/31014020PubMed
722625413Reversible Michael additions: covalent inhibitors and prodrugs.Mini Rev Med Chem2012https://conductscience.org/library/papers/22625413PubMed
817379147Covalent reactions of wortmannin under physiological conditions.Chem Biol2007https://conductscience.org/library/papers/17379147PubMed
930174151Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors.Bioorg Med Chem Lett2018https://conductscience.org/library/papers/30174151PubMed
1033175531Uncoupling the Folding-Function Paradigm of Lytic Peptides to Deliver Impermeable Inhibitors of Intracellular Protein-Protein Interactions.J Am Chem Soc2020https://conductscience.org/library/papers/33175531PubMed
1133730624Recent advances in development of hetero-bivalent kinase inhibitors.Eur J Med Chem2021https://conductscience.org/library/papers/33730624PubMed
1227330107Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics.Mol Cancer Ther2016https://conductscience.org/library/papers/27330107PubMed
1337433100Structural Basis for Variations in Polo-like Kinase 1 Conformation and Intracellular Stability Induced by ATP-Competitive and Novel Noncompetitive Abbapolin Inhibitors.ACS Chem Biol2023https://conductscience.org/library/papers/37433100PubMed
1421765407Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel.Nat Chem Biol2011https://conductscience.org/library/papers/21765407PubMed
1519774589Bisubstrate inhibitors of protein kinases: from principle to practical applications.ChemMedChem2010https://conductscience.org/library/papers/19774589PubMed
1622292814Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification.ACS Chem Biol2012https://conductscience.org/library/papers/22292814PubMed
1719597481Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1.Nat Struct Mol Biol2009https://conductscience.org/library/papers/19597481PubMed
1824564382Bivalent inhibitors of protein kinases.Crit Rev Biochem Mol Biol2014https://conductscience.org/library/papers/24564382PubMed
1916557283Targeting polo-like kinase 1 for cancer therapy.Nat Rev Cancer2006https://conductscience.org/library/papers/16557283PubMed
2015855824Overexpression of Polo-like kinase 1 is a common and early event in pancreatic cancer.Pancreatology2005https://conductscience.org/library/papers/15855824PubMed

See all 49 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
41026045
Identification of novel potent peptide inhibitors targeting the polo-box domain of PLK1: structure-based pharmacophore modelling, virtual screening, molecular docking, molecular dynamics study and biological evaluation.
J Enzyme Inhib Med Chem2025https://conductscience.org/library/papers/41026045PubMed
39764864Fine-tuning probes for fluorescence polarization binding assays of bivalent ligands against polo-like kinase 1 using full-length protein.Bioorg Med Chem2025https://conductscience.org/library/papers/39764864PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
PLK15347PubTator's text mininghttps://conductscience.org/library/genes/5347

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39092437

GET https://conductscience.org/api/papers/v1/39092437/references?page=2